abstract |
The disclosure relates compounds of general formula (I), wherein A, Y, Z, X, W, R1, R2, R3 and n are as described in the specification, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The compounds may be used to treat hyperlipidaemia, dyslipidaemia and other similar diseases. Examples of these compounds include: N-((tetrahydro-2H-pyran-4-yl)methyl)-2-((5-(1-(((4-(trifluoromethyl)benzyl)oxy)imino)propyl)pyridin-2-yl)oxy)acetamide; N-((tetrahydro-2H-pyran-4-yl)methyl)-2-((5-(1-(((4-(trifluoromethyl)benzyl)oxy)imino)propyl)pyridin-2-yl)amino)acetamide; 2-((5-(1-((benzyloxy)imino)propyl)pyridin-2-yl)oxy)-N-((tetrahydro-2H-pyran-4-yl)methyl)acetamide; 2-((5-(1-(((4-methylbenzyl)oxy)imino)propyI)pyridin-2-yl)oxy)-N-((tetrahydro-2Hpyran-4-yl)methyl)acetamide; 2-((5-(1-(((4-methoxybenzyl)oxy)imino)propyl)pyridin-2-yl)oxy)-N-((tetrahydro-2H-pyran-4-yl)methyl)acetamide; N-((tetrahydro-2H-pyran-4-yl)methyl)-2-((5-(1-(((4-(trifluoromethyl)benzyl)oxy)imino)ethyl)pyridin-2-yl)oxy)acetamide; N-((tetrahydro-2H-pyran-4-yl)methyl)-2-((5-(1-(((4-(trifluoromethyl)benzyl)oxy)imino)ethyl)pyridin-2-yl)amino)acetamide; N-((tetrahydro-2H-pyran-4-yl)methyl)-2-((4-(1-(((4-(trifluoromethyl)benzyl)oxy)imino)propyl)phenyl)amino)acetamide; 2,2’-((5-(1-(((4-(trifluoromethyl)benzyl)oxy)imino)ethyl)oxazol-2-yl)azanediyl)bis(N-((tetrahydro-2H-pyran-4-yl)methyl)acetamide). |